MedTrace Logo

Fycompa in Subjects With Small Fiber Neuropathy (SFN)

NCT02511873 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-01-27

No results posted yet for this study

Summary

This is a Phase II, 2 arm randomized crossover study. Subjects will be assigned to either active agent or placebo and then crossover to the other arm. This study is designed to evaluate whether Fycompa improves the quality of life in patients with small fiber neuropathy.

Conditions

  • Neuropathy, Small Fiber

Interventions

DRUG

Fycompa

Subjects will take Fycompa for 6 weeks with a dose range of 2mg to 8mg daily

DRUG

Placebo

Placebo (looks like study drug but has no active ingredients) for 6 weeks with a dose range of 2mg to 8mg daily

Sponsors & Collaborators

  • Eisai Inc.

    collaborator INDUSTRY

  • PNA Center for Neurological Research

    lead OTHER

Principal Investigators

  • Todd Levine, MD · PNA Center for Neurological Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02511873 on ClinicalTrials.gov